Huiliao Bio was awarded the title of "Unicorn Cultivation Enterprise" in Suzhou in 2023.

On December 27, 2023, the Suzhou Science and Technology Bureau publicized the list of companies proposed for inclusion in the 2023 Suzhou "Unicorn" Cultivation Enterprise program, with HealBio listed among them.

Amidst the burgeoning innovation and entrepreneurial landscape of Suzhou, Huiliao Biology has been recognized as a "Suzhou Unicorn Cultivation Enterprise" for its outstanding innovation capabilities and achievements, becoming a significant contributor to the city's technological advancements. This honor is a testament to the Huiliao Biology team's innovative prowess and dedication, as well as an affirmation of its contributions to the biopharmaceutical sector. Huiliao Biology is committed to upholding its innovative spirit and striving for further excellence.

#Regarding Unicorn Cultivation#

Suzhou has consistently been a pivotal city in China's economic and technological spheres, representing the economic dynamism of the Yangtze River Delta region. As a leading high-tech industrial base in China, Suzhou has been actively fostering high-tech industries and promoting technological innovation in recent years, achieving remarkable progress in cultivating unicorn enterprises.

Unicorn cultivation enterprises are startups valued at over 1 billion yuan, demonstrating exceptional performance in fields such as technology, biopharmaceuticals, new energy, and artificial intelligence. The rise of unicorn enterprises not only reflects the success of the companies themselves but also signifies the region's commitment to innovation and technology. The robustness of government support, investment institutions, and the venture capital ecosystem are crucial factors in nurturing and fostering unicorn enterprises.

#About Huiliao Biology#

Suzhou Huiliao Biology, established on May 18, 2021, is located in the Suzhou Industrial Park 2.5 Industrial Park. It is a high-tech biotech company specializing in the research and industrialization of nucleic acid drugs. The company has built a comprehensive industrialization platform based on its internationally pioneering mRNA underlying technology, dedicated to the development of next-generation vaccines and therapeutic drugs for critical clinical needs.

The company's business encompasses all aspects of mRNA drug development, including application, clinical trial design, data analysis, and industrialization. Centered around its novel mRNA delivery system—the cell membrane-like platform—Huiliao Biology is developing highly effective vaccines for infectious diseases, cancer vaccines, cell therapies, and protein replacement therapies, all based on its proprietary original technologies.